Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Shitara, Kohei; Bang, Yung‐Jue; Iwasa, Satoru; Sugimoto, Naotoshi; Ryu, Min‐Hee; Sakai, Daisuke; Cheol Chung, Hyun; Kawakami, Hisato; Yabusaki, Hiroshi; Lee, Jeeyun; Saito, Kaku; Kawaguchi, Yoshinori; Kamio, Takahiro; Kojima, Akihito; Sugihara, Masahiro; Yamaguchi, Kensei

doi:10.1056/nejmoa2004413

Public

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Published in New England Journal of Medicine • May 29, 2020

Authors:

Kohei Shitara

Yung‐Jue Bang

Satoru Iwasa

Abstract

BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. The drug may have efficacy in patients with HER2-positive advan...

Subject

Trastuzumab

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!